Leukemia treatment showdown: which First-Line therapy works best?
NCT ID NCT02938858
First seen Jan 03, 2026 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study is a registry that tracks 400 adults aged 70 or younger with a specific, less aggressive form of acute promyelocytic leukemia (APL). It compares two standard first-line treatments—ATRA plus chemotherapy versus ATRA plus arsenic trioxide—to see which is more effective and has fewer side effects. The goal is to gather real-world data to help doctors choose the best approach for each patient.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Dr Schaffner
Lens, 62307, France
-
CHR Metz-Thionville - Hôpital de Marcy
Metz, 57085, France
-
CHRU de Brest - Pédiatrie Spécialisée
Brest, 29609, France
-
CHU Bordeaux Pellegrin enfant
Bordeaux, 33076, France
-
CHU Estaing
Clermont-Ferrand, 63100, France
-
CHU Hôpital Sud - service Hémato-oncologie Pédiatrique
Rennes, 35203, France
-
CHU Hôtel Dieu
Nantes, 44035, France
-
CHU Saint Eloi
Montpellier, 34095, France
-
CHU de Grenoble
Grenoble, 38043, France
-
Centre Henri Becquerel
Rouen, 76038, France
-
Centre Hospitalier V. Dupouy
Argenteuil, 95107, France
-
Centre Hospitalier d'Aix en Provence
Aix-en-Provence, 13616, France
-
Chru - Hopital Claude Huriez
Lille, 59037, France
-
Chu Timone
Marseille, 13385, France
-
Groupe Hospitalier SUD
Amiens, 80054, France
-
Hopital Andre Mignot
Le Chesnay, 78150, France
-
Hôpital Henri Mondor
Créteil, 94100, France
-
Hôpital Jean Minjoz
Besançon, 25030, France
-
Hôpital Necker
Paris, 75015, France
-
Hôpital Robert Debré
Paris, 75019, France
-
Hôpital TROUSSEAU
Paris, 75012, France
-
Hôpital V. Provo
Roubaix, 59056, France
-
Hôpital de la Source
Orléans, 45100, France
-
Hôpital universitaire Dupuytren
Limoges, 87042, France
-
IUCT Oncopole
Toulouse, 31059, France
-
Institut Paoli Calmettes
Marseille, 13273, France
-
Institut de Cancerologie de La Loire
Saint-Priest-en-Jarez, 42270, France
Conditions
Explore the condition pages connected to this study.